Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FLT3 N676K |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FLT3 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FLT3 N676K | hematologic cancer | sensitive | FLT3 Inhibitor | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 N676K in culture (PMID: 32040554). | 32040554 |
| FLT3 N676K | acute myeloid leukemia | predicted - sensitive | FLT3 Inhibitor | Sorafenib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with acute myeloid leukemia harboring FLT3 N676K, along with NRAS G12A, KRAS G12D, ASXL1 G629fs, and GATA2 M388fs, responded to Nexavar (sorafenib) treatment (PMID: 32984009). | 32984009 |
| FLT3 N676K | hematologic cancer | sensitive | FLT3 Inhibitor | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) inhibited viability of cultured cells expressing FLT3 N676K (PMID: 38231480). | 38231480 |
| FLT3 N676K | hematologic cancer | resistant | FLT3 Inhibitor | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, cultured cells expressing FLT3 N676K were resistant to treatment with Vanflyta (quizartinib) (PMID: 38231480). | 38231480 |
| FLT3 N676K | hematologic cancer | sensitive | Foretinib | Preclinical - Cell culture | Actionable | In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3 N676K (PMID: 38231480). | 38231480 | |
| FLT3 N676K | hematologic cancer | sensitive | FLT3 Inhibitor | Gilteritinib | Preclinical | Actionable | In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 N676K in culture and inhibited growth in a transplant model (PMID: 40196870). | 40196870 |
| FLT3 N676K | hematologic cancer | resistant | FLT3 Inhibitor | Quizartinib | Preclinical | Actionable | In a preclinical study, cells expressing FLT3 N676K were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). | 40196870 |
| FLT3 N676K | hematologic cancer | decreased response | FLT3 Inhibitor | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FLT3 N676K were less sensitive to Rydapt (midostaurin) compared to cells expressing a FLT3-ITD in culture (PMID: 40196870). | 40196870 |